Sellas Life Sciences Group Inc represents values of innovation, dedication, and commitment to revolutionizing cancer treatment. With a strong corporate philosophy focused on improving patient outcomes, Sellas Life Sciences Group Inc prioritizes scientific advancements and breakthroughs. By leveraging cutting-edge technology and extensive research, the company aims to develop novel immunotherapies to address unmet medical needs in various oncology indications. Sellas Life Sciences Group Inc is dedicated to bringing hope to patients and their families by striving for personalized approaches to treatment, enhancing quality of life, and ultimately, contributing to the fight against cancer.

Sellas Life Sciences Group Inc is primarily present in the United States.

Sellas Life Sciences Group Inc has achieved several significant milestones. The company successfully completed a Phase 3 trial for its lead product candidate, galinpepimut-S, a potential immunotherapy treatment for cancer. Additionally, Sellas Life Sciences received Fast Track designation from the U.S. FDA for galinpepimut-S in acute myeloid leukemia (AML) patients in first complete remission. The company also secured orphan drug designations for multiple indications, including AML and malignant pleural mesothelioma. Sellas Life Sciences is committed to advancing these innovative therapies to address unmet medical needs and improve patient outcomes.

Sellas Life Sciences Group Inc, a leading biopharmaceutical company, has an impressive history and background. Founded in 2012 and headquartered in New York, Sellas focuses on developing novel cancer immunotherapies and therapeutics. The company is dedicated to improving patient outcomes and addressing unmet medical needs. Sellas has made significant strides in the field of cancer treatments, leveraging its expertise in innovative immunotherapeutic platforms. With a strong emphasis on research and development, Sellas has collaborated with renowned institutions and researchers to advance its pipeline of products. With its commitment to transformative medical advancements, Sellas Life Sciences Group Inc continues to contribute significantly to the fight against cancer.

The main competitors of Sellas Life Sciences Group Inc in the market include company names such as Bristol-Myers Squibb, AstraZeneca, Novartis, and Merck & Co. These pharmaceutical companies also operate in the field of oncology, immunotherapy, and cancer therapeutics. Sellas Life Sciences Group Inc faces competition from these industry leaders in terms of drug development, market presence, and research efforts.

Sellas Life Sciences Group Inc is primarily active in the biotechnology industry.

The business model of Sellas Life Sciences Group Inc is focused on the development and commercialization of novel cancer immunotherapies. Sellas aims to treat a wide range of cancers by targeting the body's immune system to fight and eliminate cancer cells. The company's pipeline includes innovative and potential drug candidates that aim to address the substantial unmet medical needs in various indications. Sellas Life Sciences Group Inc employs a patient-focused approach with a commitment to advancing groundbreaking therapies that have the potential to improve outcomes and quality of life for cancer patients.

Raportul Sellas Life Sciences Group preț/beneficiu este -0,90.

Raportul Sellas Life Sciences Group preț/vânzări este 0.

Scorul de calitate AlleAktien pentru Sellas Life Sciences Group este 5/10.

Cifra de afaceri nu poate fi calculată în prezent pentru Sellas Life Sciences Group.

Profitul așteptată Sellas Life Sciences Group este -37,36 milioane USD.

Sellas Life Sciences Group Inc is a biotechnology company specialized in the development and commercialization of innovative therapies for cancer patients. The company focuses on three areas: research and development, technology licensing, and global product marketing. The main focus of Sellas Life Sciences is researching cancer immunotherapies that enable the body's immune system to fight cancer cells. The company has an extensive portfolio of clinical trials focusing on various types of cancer, including breast, lung, and prostate cancer. Research and development at Sellas Life Sciences involve creating drugs that can be used as standalone therapy or in combination with other treatment options. Sellas Life Sciences holds numerous patents for its technologies focusing on biomarkers, diagnostic procedures, and therapies for cancer patients. The company also has partnerships with various pharmaceutical and biotechnology companies to license and market its technologies and patents. In terms of marketing, Sellas Life Sciences has a variety of products in its portfolio approved for both the US and international markets. One of the company's main products is Galinpepimut-S, an immunotherapeutic specifically developed for breast cancer treatment. The company also has other products such as NPS-1034, a kinase inhibitor for lung cancer treatment, and GPS, a diagnostic test used to detect the presence of cancer cells in patients. Sellas Life Sciences aims to expand its business in both the US and international markets. The company has distribution partnerships in Europe, Asia, Australia, and Latin America to market its products in these regions. In addition to its own sales activities, Sellas Life Sciences collaborates closely with local distributors and partners to promote its products and technologies. In research and development, the company continuously invests in the development of new therapies and technologies for cancer patients. Sellas Life Sciences collaborates with academic institutions and research centers worldwide to expand its research activities and gain new insights. In summary, Sellas Life Sciences Group Inc is an emerging biotechnology company specializing in the treatment of cancer patients. The company's business model is based on research and development, technology licensing, and global product marketing. Through its comprehensive R&D activities, licensed patents, and product portfolio, Sellas Life Sciences aims to find a cure for cancer and establish an international presence. The answer is Sellas Life Sciences Group Inc is a biotechnology company specialized in the development and commercialization of innovative therapies for cancer patients.

Sellas Life Sciences Group distribuie un dividend de 0 USD în plăți anuale.

Dividenda nu poate fi calculată în prezent pentru Sellas Life Sciences Group sau compania nu distribuie dividende.

Codul ISIN pentru Sellas Life Sciences Group este US81642T2096.

Codul WKN al Sellas Life Sciences Group este A2PU3T.

Ticker-ul pentru Sellas Life Sciences Group este SLS.

În ultimele 12 luni, Sellas Life Sciences Group a plătit un dividend în valoare de . Aceasta corespunde unei randamente a dividendului de aproximativ . Pentru următoarele 12 luni, Sellas Life Sciences Group va plăti probabil un dividend de 0 USD.

Randamentul dividendelor pentru Sellas Life Sciences Group este în prezent de .

Sellas Life Sciences Group plătește un dividend trimestrial. Acesta este distribuit în lunile .

Sellas Life Sciences Group a plătit dividende în fiecare an, în ultimii 0 ani.

Pentru următoarele 12 luni se așteaptă dividende în valoare de 0 USD. Acest lucru corespunde unei randamente a dividendelor de 0 %.

Sellas Life Sciences Group este atribuit sectorului 'Sănătate'.

Pentru a primi ultimul dividend de Sellas Life Sciences Group de la 22.09.2024 în valoare de 0 USD, trebuia să deții acțiunea în portofoliu înainte de ziua Ex-Tag de pe 22.09.2024.

Ultima plată a dividendului a fost efectuată la 22.09.2024.

În anul 2023, Sellas Life Sciences Group a distribuit 0 USD sub formă de dividende.

Dividendele de la Sellas Life Sciences Group sunt distribuite în USD.